<DOC>
	<DOCNO>NCT00694642</DOCNO>
	<brief_summary>The purpose study determine whether transendocardial injection autologous endothelial progenitor cell CD 133 safe feasible patient refractory angina .</brief_summary>
	<brief_title>Safety Efficacy Autologous Endothelial Progenitor Cell CD 133 Therapeutic Angiogenesis</brief_title>
	<detailed_description>The PROGENITOR trial randomize , double-blinded , multicenter control trial include patient Canadian cardiovascular society angina classification ( CCS ) : II-IV ischemic zone SPECT without option revascularization . Primary endpoint ass safety feasibility transendocardial injection select CD133+cells . All patient treat 4-days granulocyte colony-stimulating factor underwent apheresis . CD133+ cell select CliniMacs system inject transendocardially guide NOGA XP system .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Functional class II IV angina maximal medical therapy Myocardial Ischemia/viability demonstrate reversible perfusion defect mean image technique Patients amenable type revascularization procedure ( percutaneous surgical ) Signed informed consent Age &lt; 18 year &gt; 75 year . Atrial fibrillation . LV thrombus Acute myocardial infarction last 3 month An LV wall thickness &lt; 8 mm target site cell injection A history malignancy last 5 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Refractory angina</keyword>
</DOC>